德谷胰岛素对血糖变异性的影响研究进展

Advances in the Study of the Effect of Deglutethimide Insulin on Blood Glucose Variability

糖尿病的慢性并发症不仅与持续的高血糖有关,还与血糖变异性有关。理想的胰岛素在控制糖化血红蛋白(glycosylated hemoglobin,HbA1c)的同时,还要控制血糖变异性。德谷胰岛素(insulin degludec,IDeg)是一种超长效胰岛素类似物,作用时间超过42 h,半衰期25 h,是甘精胰岛素的2倍,在1型和2型糖尿病患者中均表现出稳定的降糖效果。与其他基础胰岛素相比,德谷胰岛素拥有较低的血糖变异性和低血糖发生率,对稳定的血糖控制具有显著效果。本文旨在对德谷胰岛素对血糖变异性影响的研究现状作一综述。

Chronic complications of diabetes mellitus are not only related to persistent hyperglycemia,but also to glycemic variability.The ideal insulin controls HbA1c along with glycemic variability.Insulin degludec is an ultra-longacting insulin analogue with an action time of over 42 hours and a half-life of 25 hours,which is twice as long as that of glargine insulin,and has shown stable glucose-lowering effects in both type 1 and type 2 diabetic patients.Compared with other basal insulins,degludec insulin possesses lower glycemic variability and hypoglycemia incidence,and has a significant effect on stable glycemic control.The purpose of this paper is to review the current research on the effect of degludec insulin on glycemic variability.